Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis

BACKGROUND: After the approval of pazopanib for the treatment of soft tissue sarcoma (STS), pneumothorax was reported as an unexpected adverse event during pazopanib treatment. The incidence and risk factors of pneumothorax during pazopanib treatment for STSs have not been established yet. METHODS:...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Nakano, Kenji, Motoi, Noriko, Tomomatsu, Junichi, Gokita, Tabu, Ae, Keisuke, Tanizawa, Taisuke, Matsumoto, Seiichi, Takahashi, Shunji
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5035441/
https://ncbi.nlm.nih.gov/pubmed/27663525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2786-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi